Colesco supports the refinancing of Ace Pharmaceuticals, a portfolio company of Rivean Capital, Gilde Healthcare and Quadrum Capital
Utrecht, 27/03/2025 – Colesco, a sustainability-led direct lender established to support leading European mid-market businesses that contribute to the transition to a more sustainable society, is pleased to announce that it has provided financing to Ace Pharmaceuticals BV ("Ace"), a leading independent pharmaceutical company specialising in niche medical need products. These niche medicines are often underserved by big pharmaceutical companies due to the lower volumes and complex (re-)development needs. By meeting the demands of these small, specific patient groups, Ace makes a valuable contribution to the accessibility and affordability of healthcare, which fully aligns with Colesco’s Inclusive Society investment philosophy.
Ace focuses on the development, registration, production and distribution of licensed and unlicensed medicines to pharmaceutical wholesalers and pharmacies. The company also produces and delivers compounded products to retail pharmacies and hospitals.
The unitranche loan provided by Colesco will be used to refinance Ace’s existing facilities, as well as provide an acquisition line to support growth and fund add-on opportunities. Ace aims to further strengthen its market position by expanding its registered product portfolio through new (international) product launches and growing its compounding activities.
Jacco Rolvink, Co-Head of Origination at Colesco said: “This investment stood out to us as we saw a clear fit with our Inclusive Society investment philosophy by increasing the accessibility of healthcare. There is often no alternative available for Ace’s products. By redeveloping, registering, and producing these medicines, Ace ensures a continuity in the supply of products which would otherwise disappear from the market. Medicine shortage has increased over the years, and companies such as Ace can help to solve this issue for small patient populations.”
Tom Muizers, Senior Partner at Rivean Capital commented on behalf of the shareholders: “We are delighted to have Colesco onboard as our financing partner. The new debt facility provides the scale growth for Ace. Together with Colesco, we can accelerate our strong growth trajectory through selected acquisitions and new product launches, while continuing to ensure that medical need products remain available at a fair price for patients for whom no substitute is available.”
For further information please contact:
Amy Williams,amy@whitewillowpr.com,+44 (0) 7734671067
About Colesco
Colesco is an innovative direct lender and investment platform for institutional investors, with a mission to unite capital and purpose. It provides senior secured and subordinated debt to leading European mid-market companies (between €10m-€100m EBITDA) that seek to achieve their sustainable growth ambitions.
With a clear focus on thematic investing and a wide network in both its home market of the Benelux and across Europe, Colesco offers investors the advantages of a growing sustainable private debt market, while being a reliable, long-term partner to companies that want to realise their growth ambitions.
Please find more information on our approach here: www.colescocapital.com
Follow Colesco on LinkedIn